Altimmune Holds $480 Million To Back Its Experimental Liver-Drug Program

Liver-disease trials pushed development spending to $27.0 million, while the next FDA meeting is scheduled for December.

Share
Altimmune Holds $480 Million To Back Its Experimental Liver-Drug Program

Altimmune, which is testing pemvidutide for serious liver diseases, reported $480 million in cash, cash equivalents and investments Thursday. The September 30 balance backs a company with no drugs approved for sale and a late-stage liver-disease readout anticipated in 2029, according to its earnings release accompanying the SEC filing.

Liver Trials Take More Cash

Third-quarter research and development spending rose to $27.0 million from $15.0 million a year earlier. Altimmune attributed most of the increase to its late-stage MASH study and mid-stage alcohol-associated liver-disease trial. Direct spending on pemvidutide accounted for $20.3 million.

The quarterly loss widened to $31.6 million from $19.0 million, but loss per share narrowed to $0.15 from $0.21. Average shares used in the calculation rose to 205,273,395 from 89,418,028, spreading the larger loss across a larger share base.

Administrative costs increased to $8.7 million from $5.9 million, mainly because of pay and professional services, the company said. Interest income rose to $4.8 million from $2.4 million.

For the first nine months, development spending reached $61.9 million, compared with $48.0 million a year earlier. The loss for that period widened to $77.0 million from $60.7 million.

One Drug, Multiple Clinical Bets

Pemvidutide is an experimental weekly injection that activates glucagon and GLP-1 receptors. Altimmune is developing it for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder and alcohol-associated liver disease. Its business depends on candidates succeeding in clinical testing and regulatory review.

The global late-stage MASH trial began in July 2026. Jerry Durso, Altimmune's chief executive and board chairman, said Thursday, “Our global PERFORMA Phase 3 trial in MASH is ramping up”. The company expects initial results covering 52 weeks of treatment in 2029.

The FDA has given pemvidutide Breakthrough Therapy designation for MASH, based on 24-week mid-stage data, and Fast Track designations for MASH and alcohol use disorder. The company's 48-week MASH findings were published in The Lancet Gastroenterology & Hepatology.

Altimmune announced alcohol-use-disorder results in July, with additional findings presented Monday in Denver. In a study of about 100 participants receiving medication or placebo with behavioral treatment, weekly heavy-drinking days fell by 4.2 with pemvidutide, compared with 2.75 with placebo.

Enrollment in the mid-stage alcohol-associated liver-disease study finished in August 2026. Altimmune expects results in the second half of 2027.

The next scheduled regulatory step is a December 2026 FDA meeting to discuss Altimmune's proposed late-stage alcohol-use-disorder program.

Sources

More on Altimmune

All Altimmune (ALT) coverage →